New review illuminates the future of AI in pathology

Pathology, the gold standard for disease diagnosis, is undergoing a profound transformation. The shift from traditional microscopy to digital pathology, powered by whole-slide imaging (WSI), has opened the door for artificial intelligence (AI) to revolutionize diagnostic and prognostic workflows. However, a critical gap persists between the rapid advancements in AI algorithms and the practical demands of clinical practice. Pathologists need tools that are not only accurate but also interpretable, reliable, and seamlessly integrated into their work.

To bridge this divide, a team of researchers led by Prof. Xing-hua Gao from The First Hospital of China Medical University and Prof. Xiao-yu Cui from Northeastern University has published a comprehensive review. Their work introduces a novel framework for systematically connecting cutting-edge deep learning technologies with core clinical tasks in pathology. The review, which analyzes the field from 2020 to 2025, was made available online on July 22, 2026 and published in Chinese Medical Journal.

“The challenge isn’t just about creating powerful algorithms; it’s about making them clinically relevant and actionable,” explains Prof. Gao. “We introduced a dual-perspective framework that maps specific deep learning architectures—like CNNs, Vision Transformers, and Graph Neural Networks—to essential clinical needs such as diagnostic classification, tissue segmentation, and prognostic prediction. This provides a much-needed roadmap for developing AI solutions that truly address the challenges pathologists face every day.”

The review highlights how these advanced AI models are already making an impact. For instance, Vision Transformers can achieve over 94% accuracy in classifying oral epithelial dysplasia, while other models can predict cancer patient survival directly from standard H&E-stained slides, reducing the reliance on more expensive and time-consuming genetic tests. The paper also points to the landmark FDA approval of the Paige Prostate AI system as a sign that the digital era of pathology has truly arrived.

A significant hurdle for developing pathology AI is the need for vast amounts of expertly annotated data, which is both time-consuming and costly to produce. The review details emerging trends that tackle this bottleneck, including weakly supervised and self-supervised learning methods that minimize the reliance on these costly annotations. These approaches allow AI models to learn from large, unlabeled datasets, accelerating development and deployment.

“Our goal is to foster the development of AI systems that enhance, rather than replace, the invaluable expertise of pathologists,” notes Prof. Cui. “This means focusing on critical challenges like model interpretability, ensuring regulatory approval, and validating performance across multiple medical centers. The future lies in creating integrated, trustworthy, and equitable AI that becomes an indispensable partner in clinical decision-making.”

By providing a systematic overview and a clear algorithm-to-task mapping, the review serves as a vital resource for both researchers developing the next generation of AI tools and clinicians looking to integrate them into practice. The authors conclude with a forward-looking vision for a future where computational pathology tools are seamlessly woven into the fabric of clinical care, ultimately improving diagnostic accuracy and patient outcomes.

***

Reference
Title of original paper: Deep learning-based computational pathology: Technologies, clinical applications, and future directions

Journal: Chinese Medical Journal

DOI: 10.1097/CM9.0000000000004154

Funding
This work was supported by the National Key R&D Program of China (Grant No. 2023YFC2508200) and National Natural Science Foundation of China (Grant Nos. 82573977 and 82373483).